Excision repair cross complementation group 1 immunohistochemical expression predicts objective response and cancer-specific survival in patients treated by Cisplatin-based induction chemotherapy for locally advanced head and neck squamous cell carcinoma.

doi:10.1158/1078-0432.CCR-07-0252

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Excision repair cross complementation group 1 immunohistochemical expression predicts objective response and cancer-specific survival in patients treated by Cisplatin-based induction chemotherapy for locally advanced head and neck squamous cell carcinoma.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Jul 2007

Handra-Luca Adriana, Hernandez Juana, Mountzios Giannis, Taranchon Estelle, Lacau-St-Guily Jean, Soria Jean-Charles, Fouret Pierre

Abstract excerpt

PURPOSE: To assess the correlation of excision repair cross complementation group 1 (ERCC1) immunohistochemical expression with objective tumor response and cancer-specific survival in patients with locally advanced head and neck squamous cell carcinoma treated with cisplatin-based induction chemotherapy. EXPERIMENTAL DESIGN: The initial cohort was composed of 107 patients who were treated from 1992 to 1996 by an...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Squamous Cell

Share to Cisplatin

Share to Endonucleases

Share to Head and Neck Neoplasms

Share to Immunohistochemistry

Share to Neoplasms

Share to Treatment Outcome

Source

Open in PubMed

Identifiers

PMID: 17606717
DOI: 10.1158/1078-0432.CCR-07-0252

Genes

ERCC1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Excision repair cross complementation group 1 immunohistochemical expression predicts objective response and cancer-specific survival in patients treated by Cisplatin-based induction chemotherapy for locally advanced head and neck squamous cell carcinoma.PMID 17606717Read ↗

Predictive Role of ERCC1 Expression in Head and Neck Squamous Cell Carcinoma Patients Treated with Surgery and Adjuvant Cisplatin-Based Chemoradiation.Semantic proximity Read ↗

Comparing ERCC1 protein expression, mRNA levels, and genotype in squamous cell carcinomas of the head and neck treated with concurrent chemoradiation stratified by HPV status.Semantic proximity Read ↗

Molecular Characteristics of ERCC1-Negative versus ERCC1-Positive Tumors in Resected NSCLC.Semantic proximity Read ↗

ERCC1 expression by immunohistochemistry and EGFR mutations in resected non-small cell lung cancer.Semantic proximity Read ↗

ERCC1 Isoform Expression and DNA Repair in Non–Small-Cell Lung CancerSemantic proximity Read ↗

ERCC1 C8092A polymorphism predicts fair survival outcome in Japanese patients with pharyngo-laryngeal squamous cell carcinoma.Semantic proximity Read ↗

High expression of excision repair cross-complementation group1 protein predicts poor outcome in patients with nasopharyngeal cancerSemantic proximity Read ↗

Expression of excision repair cross-complementation group 1 protein predicts poor outcome in advanced non-small cell lung cancer patients treated with platinum-based doublet chemotherapySemantic proximity Read ↗

Pre-treatment tumor expression of ERCC1 in women with advanced stage epithelial ovarian cancer is not predictive of clinical outcomes: a Gynecologic Oncology Group study.Semantic proximity Read ↗

Nucleotide Excision Repair Pathways Involved in Cisplatin Resistance in Non-Small-Cell Lung CancerSemantic proximity Read ↗

Disease-free survival of patients after surgical resection of non-small cell lung carcinoma and correlation with excision repair cross-complementation group 1 expression and genotype.Semantic proximity Read ↗

Radiotherapy modulates expression of EGFR, ERCC1 and p53 in cervical cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.